Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

BACKGROUND: Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer Society (AIO) 0604 trial, tri-weekly XELIRI plus bevacizumab, with reduced...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Chin J Cancer
Main Authors: Kotaka, Masahito, Xu, Ruihua, Muro, Kei, Park, Young Suk, Morita, Satoshi, Iwasa, Satoru, Uetake, Hiroyuki, Nishina, Tomohiro, Nozawa, Hiroaki, Matsumoto, Hiroshi, Yamazaki, Kentaro, Han, Sae-Won, Wang, Wei, Ahn, Joong Bae, Deng, Yanhong, Cho, Sang-Hee, Ba, Yi, Lee, Keun-Wook, Zhang, Tao, Satoh, Taroh, Buyse, Marc E., Ryoo, Baek-Yeol, Shen, Lin, Sakamoto, Junichi, Kim, Tae Won
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2016
Fag:
Study Protocol
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5178089/
https://ncbi.nlm.nih.gov/pubmed/28007025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0166-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker